Arctoris and Evariste Technologies announce a joint venture to develop novel small molecule kinase inhibitors for non-small cell lung cancer (NSCLC)
Around 85% of ALS patients suffer from a progressive loss of bulbar functionality
The company plans to establish a state-of-the-art greenfield pharma facility with a total of 4-6 manufacturing units in different therapeutics categories to cater to domestic and export markets
A simple blood test detects over 30 types of cancers
The approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer
According to an Injury Surveillance Report by NCA last year, 14.75 % of players sustained shoulder injuries, 13.11% of players sustained knee injuries and almost 74 % players suffer from career-threatening Anterior Cruciate Ligament (ACL) injuries in the 1st two years of return to sport
Novel technology combines ACUVUE daily disposable contact lenses with an established antihistamine in FDA- first in its new category
The company also reported the issuance of an additional U.S. patent covering the drug, and the filing of a continuation patent application intended to expand patent coverage to other facets of the drug
ChipCytometry delivers single-cell targeted spatial proteomics for complex whole-tissue analysis of the tumour microenvironment, as well as deep immune profiling for applications in immunology, neuroscience, and infectious disease
A total of 17 labs will be operational across the country by this month
Subscribe To Our Newsletter & Stay Updated
